The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 24, 2016
Filed:
Mar. 30, 2012
Applicants:
Michelle Nannini, South San Francisco, CA (US);
Deepak Sampath, South San Francisco, CA (US);
Inventors:
Michelle Nannini, South San Francisco, CA (US);
Deepak Sampath, South San Francisco, CA (US);
Assignee:
Genentech, Inc., South San Francisco, CA (US);
Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 31/519 (2006.01); C07D 239/70 (2006.01); C07D 403/12 (2006.01); A61K 31/437 (2006.01); A61K 31/496 (2006.01); A61K 31/517 (2006.01); A61K 31/58 (2006.01); A61K 31/282 (2006.01); A61K 31/337 (2006.01); A61K 31/4188 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/704 (2006.01); A61K 39/395 (2006.01); A61K 31/436 (2006.01); A61K 31/138 (2006.01); A61K 31/4166 (2006.01); A61K 31/495 (2006.01); A61K 31/555 (2006.01); A61K 31/7068 (2006.01); C07K 16/40 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07D 403/12 (2013.01); A61K 31/138 (2013.01); A61K 31/282 (2013.01); A61K 31/337 (2013.01); A61K 31/4166 (2013.01); A61K 31/4188 (2013.01); A61K 31/436 (2013.01); A61K 31/437 (2013.01); A61K 31/4745 (2013.01); A61K 31/495 (2013.01); A61K 31/496 (2013.01); A61K 31/513 (2013.01); A61K 31/517 (2013.01); A61K 31/519 (2013.01); A61K 31/555 (2013.01); A61K 31/58 (2013.01); A61K 31/704 (2013.01); A61K 31/7068 (2013.01); A61K 39/3955 (2013.01); C07D 239/70 (2013.01); C07K 16/40 (2013.01); A61K 2039/505 (2013.01);
Abstract
The invention provides a combination of a) a compound of Formula (Ia): or a pharmaceutically acceptable salt thereof, and b) abiraterone or a pharmaceutically acceptable salt thereof for the prophylactic or therapeutic treatment of a hyperproliferative disorder, such as cancer.